MedTrace Logo

Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis

NCT00565279 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2008-06-03

No results posted yet for this study

Summary

A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.

Conditions

  • Seborrheic Dermatitis

Interventions

DRUG

ASF1057

Twice daily, topical

DRUG

ASF1057

Twice daily, Topical

Sponsors & Collaborators

  • Astion Pharma A/S

    lead INDUSTRY

Principal Investigators

  • Peder M Andersen, MD · Astion Pharma A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-05-31
Completion
2008-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565279 on ClinicalTrials.gov